A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Haemangiosarcoma; Leiomyosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 06 Mar 2017 Planned End Date changed from 1 Mar 2021 to 1 Mar 2019.
- 06 Mar 2017 Planned primary completion date changed from 1 Mar 2021 to 1 Mar 2019.
- 30 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.